Parkinson’s disease (PD) is the second most common neurodegenerative disease in world, but current symptomatic therapies are of limited value and have unwanted side-effects. Through the use of new genetic tools to manipulate and monitor the function of neurons in the brain regions responsible for PD, we have found that a particular type of neuron plays a pivotal role in both the core motor symptoms of PD and dyskinetic side-effects of the gold standard treatment for PD – levodopa. The proposed studies will build upon this discovery to forge a better understanding the cellular and molecular mechanisms underlying PD in the hope that this will lead us to new symptomatic therapies that are more effective and less burdened by side-effects.
|Effective start/end date||7/1/20 → 6/30/24|
- National Institute of Neurological Disorders and Stroke (2R37NS034696-24)